All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • Market intelligence reports
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 12, 2019

Cardiovascular

Home » Topics » Disease categories and therapies » Cardiovascular
  • Neuron-network
    December 11, 2019
    By Nuala Moran

    Scientists create artificial neurons capable of mimicking biological counterparts

    LONDON – Scientists in the U.K. are claiming a world first, after successfully reproducing the electrophysiology of biological neurons in silicon chips. It is said that artificial neurons respond to non-linear physiological feedback in real time, in exactly the same way as their biological counterparts. Crucially, in terms of their use in medical implants, the analogue chips have a power consumption 109 times lower than equivalent digital microprocessors, which other attempts to make synthetic neurons have used.
  • Newco-seedling
    December 11, 2019
    By Jihyun Kim

    Matricelf wins SEED AWARD with 3D printing heart design

    HONG KONG – Matricelf Ltd., an Israeli medical 3D printing company based in Tel Aviv, has won a SEED AWARD and the ¥1 million (US$143,000) that goes with the prize. The Global Final of the SEED AWARD 2019 was held in Shenzhen, China. The organizer Seedland Group, China’s leading real estate company promoting technology innovation, said that Matricelf is working toward one day being able to manufacture the world’s first functional 3D printed human heart.
  • December 10, 2019
    By Elise Mak

    With another $26M, Japan’s Heartseed aims to advance iPSC-derived regenerative medicine for heart failure

    BEIJING – Tokyo-based biotech firm Heartseed Inc., which focuses on regenerative medicine, has closed a series B financing round to pocket $26 million that will go to its lead drug candidate, HS-001, for treating heart failure.
Read More

Blog Posts

  • June 30, 2016
    By Mark McCarty

    Loose the clown posse; Uncle Sam has cancer fever

  • February 26, 2016
    By Omar Ford

    Rough start to 2016: J&J lays off 3,000

  • January 28, 2016
    By Omar Ford

    Momma said there'd be days like this: Heartware pauses trial again

  • June 19, 2014
    By Amanda Pedersen

    Throwback Thursday: MDD revisits 2005/2006 Guidant drama

  • November 15, 2013
    By Amanda Pedersen

    Cutting the fat, without actually cutting

Read More

Authors

  • Holland Johnson
  • Mark McCarty
  • Omar Ford
  • Jim Stommen
  • Amanda Pedersen
  • Robert Kimball
More Authors
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Archives
    • Contact us
    • Cookie policy
    • Copyright notice
    • Privacy policy
    • Share your news
    • Staff
    • Terms of use
Follow Us

Copyright ©2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing